Physician profile
Matthew Alan Fraley
NPI 1326187352
$182,646.18
in general payments reported to CMS, 2019-2025
38 companies · $277 in 2025
The $277 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101K · 2020: $18K · 2021: $16K · 2022: $26K · 2023: $13K · 2024: $7,646 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $4,137 · Travel and Lodging: $173 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,689.00 |
| Food and Beverage | $4,137.29 |
| Travel and Lodging | $172.86 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $160,788.26 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $15,213.50 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $1,407.35 | 2019-2025 | |
| Amgen INC. | $812.88 | 2019-2025 | Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $442.44 | 2019-2024 | |
| Pfizer INC. | $412.20 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $369.78 | 2019-2024 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $358.46 | 2019-2024 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $337.05 | 2019-2025 | Evkeeza, Praluent |
| Merck Sharp & Dohme LLC | $322.20 | 2022-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $310.29 | 2019-2024 | Farxiga, Brilinta, Wainua |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $278.99 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $254.84 | 2019-2024 | Watchman Access System, Watchman Flx |
| Scpharmaceuticals INC. | $172.70 | 2023-2025 | |
| Esperion Therapeutics, INC. | $123.59 | 2021-2023 | Nexletol |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $110.37 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $110.17 | 2021-2024 | |
| Novo Nordisk INC | $100.79 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $87.60 | 2022-2023 | Micra |
| Cvrx, INC. | $84.79 | 2021-2025 | Barostim Neo System |
| Daiichi Sankyo INC. | $57.85 | 2019-2022 | |
| Lexicon Pharmaceuticals, INC. | $55.61 | 2023-2024 | Inpefa |
| Alnylam Pharmaceuticals INC. | $48.63 | 2024-2025 | Onpattro, Amvuttra |
| Edwards Lifesciences Corporation | $45.45 | 2019-2020 | |
| Astellas Pharma US INC | $43.89 | 2020-2021 | |
| Abbott Laboratories | $36.93 | 2020-2022 | |
| Irhythm Technologies, INC. | $34.73 | 2019-2023 | Zio Xt Patch |
| Heartflow, INC. | $31.42 | 2024 | |
| Abiomed | $30.79 | 2024 | Impella |
| Gilead Sciences, INC. | $26.52 | 2019 | |
| Arbor Pharmaceuticals, INC. | $24.40 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $21.05 | 2023 | Arcalyst |
| Lundbeck LLC | $17.01 | 2019 | |
| Azurity Pharmaceuticals, INC. | $16.57 | 2024 | Edarbi |
| Lilly USA, LLC | $15.80 | 2019 | |
| Vifor Pharma, INC. | $15.01 | 2019 | |
| Abbvie INC. | $14.15 | 2023 | |
| Amryt Pharma Holdings LTD | $12.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Fraley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.